| View |
|
DRP-13475-04
|
Ipratropium Bromide + Salbutamol (as Sulfate)
|
Oranair Plus
|
500 mcg/2.5 mg per 2.5 mL
|
Solution for Inhalation
|
Adrenergic in combination with anticholinergic
|
Legency Remedies Pvt. Ltd.
|
India
|
CLIDP Conversion
|
26 February 2024
|
27 February 2028
|
| View |
|
DRP-13558-02
|
Lapatinib (as ditosylate monohydrate)
|
Lapinitab
|
250 mg
|
Film-Coated Tablet
|
Antineoplastic Agent
|
BDR Pharmaceuticals International Pvt. Ltd.-Oncology Unit
|
India
|
CLIDP Conversion
|
01 March 2024
|
09 March 2028
|
| View |
|
DRP-13586-01
|
Moxifloxacin (as Hydrochloride) + Dexamethasone Phosphate (as Sodium)
|
Moxfoz DM
|
5 mg/1 mg per mL (0.5% w/v/ 0.1% w/v)
|
Sterile Ophthalmic Solution
|
Antibacterial (Fluoroquinolone)/ Corticosteroid (Glucocorticoid)
|
Indiana Ophthalmics
|
India
|
CLIDP Conversion
|
18 February 2024
|
14 March 2028
|
| View |
|
DRP-13587-01
|
Moxifloxacin (as Hydrochloride)
|
Moxfloz
|
5 mg / mL (0.5% w/v)
|
Sterile Ophthalmic Solution
|
Antibacterial (Fluoroquinolone)
|
Indiana Ophthalmics
|
India
|
CLIDP Conversion
|
01 March 2024
|
14 March 2028
|
| View |
|
DRP-13645-01
|
Sitagliptin (as phosphate)
|
Sitagen
|
50 mg
|
Film-Coated Tablet
|
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
14 February 2024
|
22 March 2028
|
| View |
|
DRP-13645-02
|
Sitagliptin (as phosphate)
|
Tiglipza
|
50 mg
|
Film-Coated Tablet
|
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
06 February 2024
|
22 March 2028
|
| View |
|
DRP-13646-01
|
Sitagliptin (as phosphate)
|
Sitagen
|
100 mg
|
Film-Coated Tablet
|
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
21 January 2024
|
22 March 2028
|
| View |
|
DRP-13646-02
|
Sitagliptin (as phosphate)
|
Tiglipza
|
100 mg
|
Film-Coated Tablet
|
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
|
Magbro Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
01 March 2024
|
22 March 2028
|
| View |
|
DRP-13704-01
|
Betahistine hydrochloride
|
Bevert
|
16 mg
|
Tablet
|
Antivertigo preparation
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
01 March 2024
|
29 March 2028
|
| View |
|
DRP-13705-01
|
Betahistine hydrochloride
|
Bevert
|
8 mg
|
Tablet
|
Antivertigo preparation
|
Magbro Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
18 February 2024
|
29 March 2028
|
| View |
|
DRP-13706-01
|
Betahistine hydrochloride
|
Bevert
|
24 mg
|
Tablet
|
Antivertigo preparation
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
18 February 2024
|
29 March 2028
|
| View |
|
DRP-13724-01
|
Lactitol monohydrate
|
Lacsomitol
|
10 g per 15 mL (66.67% w/v)
|
Syrup
|
Laxative
|
Tirupati Medicare Ltd
|
India
|
CLIDP Conversion
|
19 February 2024
|
17 August 2026
|
| View |
|
DRP-13727-01
|
Rosuvastatin (as calcium)
|
Rosgen
|
10 mg
|
Film-Coated Tablet
|
HMG-CoA Reductase Inhibitor
|
Magbro Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
02 February 2024
|
04 April 2028
|
| View |
|
DRP-13778-01
|
Losartan Potassium
|
Besartan
|
50 mg
|
Film-Coated Tablet
|
Angiotensin II Receptor Blocker
|
Berlin Pharmaceutical Industry Co., Ltd
|
Thailand
|
CLIDP Conversion
|
23 January 2024
|
18 February 2029
|
| View |
|
DRP-13815-01
|
Salbutamol (as sulfate)
|
Xensal
|
2mg/5mL
|
Syrup
|
Selective Beta-2 Adrenoreceptor Agonist
|
Lloyd Laboratories, Inc.
|
Philippines
|
CLIDP Conversion
|
06 February 2024
|
19 October 2027
|
| View |
|
DRP-13833-02
|
Apixaban
|
Valixyr 2.5
|
2.5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Unison Pharmaceutical Pvt. Ltd.
|
India
|
CLIDP Conversion
|
02 May 2024
|
26 April 2028
|
| View |
|
DRP-13892-01
|
Gliclazide
|
Goclaz 30
|
30 mg
|
Modified Release Tablet
|
Blood Glucose Lowering Drug (Sulfonylurea)
|
Fredun Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
12 February 2024
|
12 May 2028
|
| View |
|
DRP-13970-01
|
Bisacodyl
|
Bisacoden
|
10mg
|
Suppository
|
Laxative
|
Y.S.P Industries (M) Sdn. Bhd.
|
Malaysia
|
CLIDP Conversion
|
24 January 2024
|
03 February 2029
|
| View |
|
DRP-13983-02
|
Apixaban
|
Abanvex 5
|
5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
19 December 2023
|
31 May 2028
|
| View |
|
DRP-13983-03
|
Apixaban
|
Profixamed
|
5 mg
|
Film-Coated Tablet
|
Antithrombotic agent (Direct factor Xa inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
18 February 2024
|
31 May 2028
|